<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Hermansky-Pudlak syndrome
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Hermansky-Pudlak syndrome
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Hermansky-Pudlak syndrome
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer L Hand, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Moise L Levy, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 16, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2084795969">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hermansky-Pudlak syndrome (HPS) is a rare autosomal recessive disorder characterized by oculocutaneous albinism, a bleeding diathesis, and other organ involvement specific to certain types [
         <a href="#rid1">
          1-3
         </a>
         ]. Eleven types of HPS associated with mutations in 11 different genes have been recognized  (
         <a class="graphic graphic_table graphicRef115599" href="/z/d/graphic/115599.html" rel="external">
          table 1
         </a>
         ). These mutations each cause altered biogenesis of lysosomes and lysosome-related organelles and defective intracellular protein trafficking.
        </p>
        <p>
         This topic will review the pathogenesis, clinical manifestations, diagnosis, and management of HPS. Oculocutaneous albinism and Chediak-Higashi syndrome, another type of syndromic oculocutaneous albinism associated with severe immunodeficiency, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15469.html" rel="external">
          "Oculocutaneous albinism"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3926.html" rel="external">
          "Chediak-Higashi syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2618790066">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hermansky-Pudlak syndrome (HPS) is rare, with a prevalence of 1 to 9 in 1,000,000 individuals worldwide [
         <a href="#rid4">
          4
         </a>
         ], but is more common in certain populations. As an example, the prevalence is 1 in 1800 individuals in Northwest Puerto Rico, where approximately 1 in 21 individuals are carriers of the mutation [
         <a href="#rid5">
          5,6
         </a>
         ]. Most HPS type 1-affected individuals in Puerto Rico have the same founder 16-base-pair duplication in exon 15 of
         <em>
          HPS1
         </em>
         [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2034377728">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hermansky-Pudlak syndrome (HPS) is caused by homozygous or compound heterozygous mutations in 1 of 11 genes that encode components in one of four HPS protein-associated complexes: adapter protein 3 (AP-3) and biogenesis of lysosome-related organelles complex 1, 2, and 3 (BLOC-1, BLOC-2, and BLOC-3). All four complexes support intracellular biogenesis, trafficking, and homeostasis of lysosome or lysosome-related organelles (LROS)  (
         <a class="graphic graphic_table graphicRef115599" href="/z/d/graphic/115599.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,8,9
         </a>
         ]. LROS include melanosomes, platelet dense bodies (also called delta granules), Weibel-Palade bodies in vascular endothelium, lamellar bodies of alveolar type II pneumocytes, and granule proteins of cytotoxic and suppressor T cells and natural killer (NK) cells [
         <a href="#rid8">
          8,10,11
         </a>
         ].
        </p>
        <p>
         The hypopigmentation in HPS is secondary to impaired melanosome formation, trafficking, or transfer to keratinocytes, while the melanin biosynthesis in melanocytes is unaffected [
         <a href="#rid8">
          8
         </a>
         ]. Immature and abnormal melanosomes cause reduced pigmentation of hair, skin, and eyes. In contrast, oculocutaneous albinism is caused by mutations in genes encoding proteins involved in the melanin biosynthesis pathway. (See
         <a class="medical medical_review" href="/z/d/html/15469.html" rel="external">
          "Oculocutaneous albinism", section on 'Defective melanin biosynthesis'
         </a>
         .)
        </p>
        <p>
         The platelet dense bodies, which play a role in secondary platelet aggregation, are absent in platelets from individuals with HPS, resulting in a platelet storage pool disorder and bleeding diathesis [
         <a href="#rid12">
          12,13
         </a>
         ]. The absence of platelet dense bodies can only be identified by whole mount electron microscopy. Routine blood count or smear are likely to be normal.
        </p>
        <p>
         The number of platelet dense bodies is also severely reduced in Chediak-Higashi syndrome, in which giant intracytoplasmic granules are also seen  (
         <a class="graphic graphic_picture graphicRef71313" href="/z/d/graphic/71313.html" rel="external">
          picture 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/6675.html" rel="external">
          "Inherited platelet function disorders (IPFDs)", section on 'Specific disorders'
         </a>
         .)
        </p>
        <p>
         Weibel-Palade bodies are secretory organelles within vascular endothelium that contain von Willebrand factor and other proteins. von Willebrand factor aids clotting, coagulation, and wound healing. BLOC-2 dysfunction is thought to impair von Willebrand factor secretion and contribute to bleeding [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         The pathogenesis of the organ damage associated with some types of HPS is unclear. Ceroid lipofuscin, an amorphous, autofluorescent, lipid-protein material, has been identified in abnormal lysosomes of multiple organs (including alveolar macrophages, and cells of the gastrointestinal tract, bone marrow, liver, spleen, lymph nodes, and heart) in patients with HPS. Accumulation in the cardiac muscle and kidney is less common. Ceroid lipofuscin is thought to cause granulomatous colitis (HPS type 1) and lung interstitial fibrosis in HPS types 1, 2, and 4 [
         <a href="#rid14">
          14
         </a>
         ], but the pathogenic mechanism remains largely unknown. (See
         <a class="medical medical_review" href="/z/d/html/4062.html" rel="external">
          "Genetic factors in inflammatory bowel disease", section on 'Hermansky-Pudlak syndrome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14870.html" rel="external">
          "Clinical manifestations and diagnosis of idiopathic pulmonary fibrosis"
         </a>
         .)
        </p>
        <p>
         Loss of AP-3 complex and disruption of azurophilic granules in neutrophils is thought to cause neutropenia and immunodeficiency in HPS type 2 [
         <a href="#rid15">
          15
         </a>
         ]. Immunodeficiency is also a feature of HPS types 9 and 10, although the mechanism is unclear, and immunodeficiency is not always reported [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1970705341">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         All individuals with Hermansky-Pudlak syndrome (HPS) exhibit oculocutaneous albinism and a bleeding diathesis. Other clinical manifestations, such as granulomatous colitis and pulmonary fibrosis, occur in specific types depending on the specific genetic defect.
        </p>
        <p>
         Of note, individuals with mutations affecting the same HPS protein complex (adapter protein 3 [AP-3] and biogenesis of lysosome-related organelles complex [BLOC-1, BLOC-2, or BLOC-3]) present similar clinical characteristics  (
         <a class="graphic graphic_table graphicRef115599" href="/z/d/graphic/115599.html" rel="external">
          table 1
         </a>
         ). Mutations in BLOC-1 (HPS types 7, 8, 9, and 11) and BLOC-2 (HPS types 3, 5, and 6) produce milder symptoms, whereas variants in BLOC-3 (HPS types 1 and 4) or AP-3 (HPS types 2 and 10) are associated with more severe disease. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
         HPS types 1 and 4 are recognized as severe forms of the disorder and are associated with pulmonary fibrosis. Types 3, 5, 6, and 11 are generally associated with a milder phenotype [
         <a href="#rid17">
          17-19
         </a>
         ]. The phenotypes of the more recently described types of HPS are not complete due to the paucity of identified cases.
        </p>
        <p class="headingAnchor" id="H119271897">
         <span class="h2">
          Skin and eye findings
         </span>
        </p>
        <p>
         Patients with HPS present with decreased pigmentation of the skin and hair. The skin color is variable, ranging from white to tan, but usually lighter than that of other family members [
         <a href="#rid20">
          20
         </a>
         ]. The hair color varies from silvery-white to light brown/reddish  (
         <a class="graphic graphic_picture graphicRef115902" href="/z/d/graphic/115902.html" rel="external">
          picture 2
         </a>
         ). Older individuals may have prominent signs of solar skin damage, including skin thickening, lentigines, and actinic keratosis  (
         <a class="graphic graphic_picture graphicRef115903" href="/z/d/graphic/115903.html" rel="external">
          picture 3
         </a>
         ). Individuals with HPS have an increased risk of skin cancer, in particular, squamous cell and basal cell carcinoma.
        </p>
        <p>
         The eyes show reduced iris pigmentation and vary in color from light blue, light green, or hazel. In patients with HPS, the ocular abnormalities are similar to those seen in patients with oculocutaneous albinism and include early-onset nystagmus, ocular sensitivity to bright light, iris transillumination, reduced retinal pigmentation, foveal hypoplasia, and reduced visual acuity for age, although visual impairment is widely variable among and within specific types [
         <a href="#rid21">
          21-25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15469.html" rel="external">
          "Oculocutaneous albinism", section on 'Ocular findings'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1121493791">
         <span class="h2">
          Systemic manifestations
         </span>
        </p>
        <p class="headingAnchor" id="H1332952332">
         <span class="h3">
          Bleeding diathesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with HPS often present with a bleeding diathesis due to absent dense granules in platelets. (See
         <a class="medical medical_review" href="/z/d/html/6675.html" rel="external">
          "Inherited platelet function disorders (IPFDs)", section on 'Hermansky-Pudlak syndrome'
         </a>
         .)
        </p>
        <p>
         Affected patients may present with easy bruising; gingival bleeding; epistaxis; or prolonged bleeding with venipuncture, menstruation, after delivery, or following dental or surgical procedures, such as circumcision. The severity of bleeding varies considerably across HPS types and may be unnoticed in some [
         <a href="#rid8">
          8
         </a>
         ]. Routine coagulation studies show a prolonged bleeding time, normal prothrombin time and partial thromboplastin time, and normal platelet count and morphology. (See
         <a class="local">
          'Diagnosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3995114366">
         <span class="h3">
          Pulmonary fibrosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary fibrosis similar to idiopathic pulmonary fibrosis occurs only in patients with HPS types 1, 2, 4, and, to a milder degree, in other types  (
         <a class="graphic graphic_table graphicRef115599" href="/z/d/graphic/115599.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid2">
          2,26
         </a>
         ]. The disease is characterized by irreversible and progressive fibrosis of the lung parenchyma and interalveolar septa.
        </p>
        <p>
         The manifestations usually begin by the early 30s in HPS type 1, with earlier onset in HPS type 2. Patients have slow onset of dyspnea on exertion or at rest and a nonproductive cough, ultimately leading to the need for chronic supplementary oxygen and respiratory failure.
        </p>
        <p>
         Typical radiographic findings include subpleural and central infiltrates; ground-glass, diffuse opacities; reticulation; and subpleural honeycombing [
         <a href="#rid27">
          27
         </a>
         ]. Histopathology shows vacuolated hyperplastic type II cells with lamellar bodies in addition to macrophages with lipofuscin deposits [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14870.html" rel="external">
          "Clinical manifestations and diagnosis of idiopathic pulmonary fibrosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1314918895">
         <span class="h3">
          Granulomatous colitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         A granulomatous colitis resembling Crohn disease clinically and histologically occurs in patients with HPS types 1 and 4. Symptoms usually begin during adolescence and include abdominal pain, fever, weight loss, malabsorption, and frequent watery and bloody diarrhea [
         <a href="#rid14">
          14
         </a>
         ]. Cases of granulomatous colitis have been reported in other subtypes. The colon is involved in most cases, but typical lesions may develop through the entire gastrointestinal tract. Metastatic granulomatous skin lesions have also been reported in patients with HPS [
         <a href="#rid29">
          29,30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4070.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1232198248">
         <span class="h3">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recurrent infections due to severe neutropenia and immunodeficiency have been described in some individuals as a distinctive feature in HPS types 2 and 10 [
         <a href="#rid15">
          15,27,31-33
         </a>
         ]. Cardiomyopathy and renal failure have been rarely reported in HPS patients [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3511553140">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of Hermansky-Pudlak syndrome (HPS) is suspected in a patient with skin and hair color lighter than that of other family members, early-onset nystagmus, and one or more of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bleeding history, such as easy bruising, gingival bleeding, epistaxis, or prolonged bleeding after venipuncture, dental procedures, parturition, menstruation, circumcision, or other surgical procedures
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of respiratory problems or early-onset pulmonary fibrosis, usually starting in the early 30s (particularly for types 1 and 4, earlier for type 2)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Granulomatous colitis similar to Crohn disease (particularly for types 1 and 4)
        </p>
        <p>
        </p>
        <p>
         Laboratory studies, a comprehensive eye examination, and molecular genetic testing, if available, are necessary to establish the diagnosis.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory studies
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Electron microscopy of platelets using the "whole mount" technique (available in specialized referral laboratories) will show the absence of dense bodies. This test can establish the diagnosis of HPS.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Routine coagulation studies, including bleeding time (or the platelet function analyzer [PFA-100]), prothrombin time, partial thromboplastin time, and platelet count and morphology, typically demonstrate (see
         <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">
          "Approach to the adult with a suspected bleeding disorder"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6675.html" rel="external">
          "Inherited platelet function disorders (IPFDs)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4433.html" rel="external">
          "Platelet function testing"
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Prolonged bleeding time
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Normal prothrombin time and partial thromboplastin time
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Normal platelet count and morphology on peripheral smear
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Platelet aggregation testing (available in specialized laboratories) can demonstrate impaired secondary platelet aggregation, suggesting a storage pool disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Eye examination
         </strong>
         – In patients with suspected HPS, a comprehensive eye examination is warranted. The ocular abnormalities that support the diagnosis of HPS are similar to those found in oculocutaneous albinism and include nystagmus, high refractive errors, reduction in best-corrected visual acuity, iris transillumination, strabismus, retinal hypopigmentation, and foveal hypoplasia. (See
         <a class="medical medical_review" href="/z/d/html/15469.html" rel="external">
          "Oculocutaneous albinism", section on 'Ophthalmologic examination'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic testing
         </strong>
         – Genetic testing, if available, helps to confirm the diagnosis of HPS and determines the HPS type [
         <a href="#rid35">
          35
         </a>
         ]. This is especially relevant, as different genetic types  (
         <a class="graphic graphic_table graphicRef115599" href="/z/d/graphic/115599.html" rel="external">
          table 1
         </a>
         ) manifest phenotypic differences that impact prognosis, surveillance, and genetic counseling [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         One approach involves the use of a multigene panel containing the 11 recognized genes associated with HPS [
         <a href="#rid1">
          1
         </a>
         ]. An alternative approach is step-wise, single-gene testing guided by consideration of clinical features and ethnic background [
         <a href="#rid2">
          2
         </a>
         ]. As an example, single-gene testing for
         <em>
          HPS1
         </em>
         pathogenic variants should be performed first in persons from Northwest Puerto Rico, while the
         <em>
          HPS3
         </em>
         founder variant should be investigated in those of central Puerto Rican or Ashkenazi Jewish descent.
         <em>
          HPS1
         </em>
         and
         <em>
          HPS4
         </em>
         should be examined first in those who are severely affected or present with symptoms of pulmonary fibrosis.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2954897922">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with Hermansky-Pudlak syndrome (HPS) types associated with a mild phenotype presenting with a minimal or unrecognized bleeding tendency may be misdiagnosed with congenital nystagmus syndrome or oculocutaneous albinism (see
         <a class="medical medical_review" href="/z/d/html/15469.html" rel="external">
          "Oculocutaneous albinism"
         </a>
         ). Conversely, children with oculocutaneous albinism type 1 may display easy bruising, more easily recognized due to their lighter skin type, but do not have HPS [
         <a href="#rid37">
          37
         </a>
         ]. Other diseases that share clinical features with HPS include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chediak-Higashi syndrome
         </strong>
         – Chediak-Higashi syndrome is a rare autosomal recessive disorder characterized by oculocutaneous albinism, recurrent pyogenic infections, progressive neurologic abnormalities, mild coagulation defects, and a lymphoma-like accelerated phase. The demonstration on peripheral blood smear of giant cytoplasmic granules in neutrophils and platelets, which are always absent in HPS, establishes the diagnosis  (
         <a class="graphic graphic_picture graphicRef71313" href="/z/d/graphic/71313.html" rel="external">
          picture 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/3926.html" rel="external">
          "Chediak-Higashi syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Griscelli syndrome
         </strong>
         – Griscelli syndrome is a rare autosomal recessive disorder characterized by pigmentary dilution of skin and hair, presence of large clumps of pigment in hair shafts, and variable association with immunodeficiency, neurologic abnormalities, and manifestations of hemophagocytic lymphohistiocytosis. Microscopic examination of the hair shaft can be used to confirm the diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/3951.html" rel="external">
          "Syndromic immunodeficiencies", section on 'Griscelli syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H476661157">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of patients with Hermansky-Pudlak syndrome (HPS) involves lifelong sun protection measures, treatment of visual impairment with glasses or contact lenses, and treatment of associated systemic manifestations [
         <a href="#rid14">
          14
         </a>
         ].
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.hpsnetwork.org%2F&amp;token=u%2FUXY8mj4f2cUyB56IXs7swsr7yJTQY7jrydT2wP%2FaR60d0ifuTh5CbYS7Y234A7&amp;TOPIC_ID=115158" target="_blank">
          A support group
         </a>
         can provide advice and information for patients and families living with HPS.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sun protection
         </strong>
         – As for patients with oculocutaneous albinism, strict sun protection should begin in infancy. Measures include sun avoidance in the peak hours of the day; use of wide-brimmed hats, sunglasses, and other protective clothing; and year-round use of a broad-spectrum sunscreen with a minimum sun protection factor of 30 on all exposed skin. Because of their increased risk of skin cancer, patients with HPS should have a skin examination at 6- to 12-month intervals starting in adolescence. Patients should also be educated about the importance of skin self-examination and the recognition of concerning skin lesions, such as new lesions in sun-exposed areas, nonhealing lesions or lesions undergoing changes, and lesions associated with symptoms like pain, itching, or bleeding. (See
         <a class="medical medical_review" href="/z/d/html/15469.html" rel="external">
          "Oculocutaneous albinism", section on 'Sun protection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Refractive errors
         </strong>
         – Eye examinations should be frequently performed in the preschool years but can be reduced to yearly thereafter. Refractive errors are managed with glasses or contact lenses (see
         <a class="medical medical_review" href="/z/d/html/15469.html" rel="external">
          "Oculocutaneous albinism", section on 'Management of eye abnormalities'
         </a>
         ). However, despite refractive correction, vision often remains abnormal. Extraocular muscle surgery may be needed to align the eye in cases with strabismus and improve nystagmus with or without associated compensatory abnormal head postures. Appropriate support in school is recommended.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bleeding diathesis
         </strong>
         – Because of the associated bleeding diathesis, patients with HPS should wear a medical alert bracelet or necklace, indicating their diagnosis and bleeding tendency. Childhood vaccinations should be given according to the American Academy of Pediatrics' schedule, although caregivers should be advised about the potential for intramuscular bleeding at the vaccine site [
         <a href="#rid14">
          14
         </a>
         ]. Patients with HPS should avoid aspirin-containing products,
         <a class="drug drug_general" data-topicid="101044" href="/z/d/drug information/101044.html" rel="external">
          bismuth subsalicylate
         </a>
         , and nonsteroidal anti-inflammatory drugs (NSAIDs). Humidifiers may decrease epistaxis [
         <a href="#rid1">
          1
         </a>
         ]. Oral or other hormonal contraceptives may decrease blood loss from menstruation [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For minor bleeding, pressure and a clean dressing with petrolatum jelly with or without thrombin-soaked, absorbable gelatin are often sufficient. For patients undergoing invasive surgery with the potential for bleeding, DDAVP (1-desamino-8-D-arginine vasopressin) may be needed [
         <a href="#rid14">
          14
         </a>
         ]. Platelet transfusions are used judiciously to avoid alloimmunization, particularly in those who may later require lung transplantation. (See
         <a class="medical medical_review" href="/z/d/html/6675.html" rel="external">
          "Inherited platelet function disorders (IPFDs)", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Precautions to minimize bleeding during dental procedures may be needed, including use of DDAVP. Use of a soft toothbrush and gentle brushing technique can reduce trauma to gums [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Granulomatous colitis
         </strong>
         – If granulomatous colitis is suspected due to cramping, bowel habit changes, and/or bleeding, colonoscopy is recommended to confirm the diagnosis. Granulomatous colitis may be treated with systemic corticosteroids or other anti-inflammatory agents used for the management of Crohn disease. There are reports of severe cases successfully treated with anti-tumor necrosis factor (TNF) agents [
         <a href="#rid38">
          38-41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">
          "Medical management of moderate to severe Crohn disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary fibrosis
         </strong>
         – Patients with HPS types 1, 2, and 4 and others who are symptomatic should undergo pulmonary function tests annually starting by age 20. Early high-resolution computed tomography scans should be obtained in all patients with HPS and abnormal lung function tests [
         <a href="#rid2">
          2
         </a>
         ]. To minimize radiation exposure, chest imaging could be spaced by three- to five-year intervals, unless worsening symptoms or pulmonary function test decline prompt more frequent screening [
         <a href="#rid27">
          27
         </a>
         ]. Pulmonary infections should be treated promptly. Patients should be counseled to avoid the use of all tobacco and other inhaled products and to obtain yearly influenza, coronavirus disease 2019 (COVID-19), and respiratory syncytial virus (RSV) vaccinations. Patients who develop pulmonary fibrosis may eventually require lung transplantation [
         <a href="#rid26">
          26,27,42,43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with HPS types 1, 2, and 4, initial discussion about lung transplant evaluation is recommended as soon as there is evidence of pulmonary fibrosis progression. Bleeding complications in HPS are not considered a contraindication, since successful lung transplants are reported with successful bleeding management [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4660.html" rel="external">
          "Lung transplantation: Disease-based choice of procedure"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection prevention
         </strong>
         – For patients with HPS type 2, infection prevention with guidance from an infectious disease specialist is recommended [
         <a href="#rid1">
          1,15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3093501741">
         <span class="h1">
          GENETIC CONSULTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients should be offered genetics consultation prior to childbearing years. Parents of affected children should be offered genetics referral to assess reproductive risk in future pregnancies.
        </p>
        <p class="headingAnchor" id="H3903465972">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis is guarded in patients with Hermansky-Pudlak syndrome (HPS) who develop hemorrhagic, gastrointestinal, and pulmonary complications. Pulmonary fibrosis is the leading cause of death in these patients. The life expectancy in patients with pulmonary fibrosis is approximately 10 years after diagnosis of restrictive lung disease in the absence of lung transplantation [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1704973432">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Hermansky-Pudlak syndrome (HPS) is a rare autosomal recessive disorder characterized by oculocutaneous albinism, a bleeding diathesis, and other organ involvement, including pulmonary fibrosis and granulomatous colitis, specific to certain types. HPS prevalence is high in Northwest Puerto Rico (1 in 1800). (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – HPS is caused by mutations in genes involved in intracellular protein trafficking and biogenesis of lysosome-related organelles in a variety of tissues  (
         <a class="graphic graphic_table graphicRef115599" href="/z/d/graphic/115599.html" rel="external">
          table 1
         </a>
         ). The hypopigmentation in HPS is secondary to impaired melanosome formation, trafficking, or transfer to keratinocytes, while the melanin biosynthesis is unaffected. The bleeding diathesis is caused by the absence of platelet dense bodies, which are involved in secondary platelet aggregation. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – All individuals with HPS exhibit oculocutaneous albinism  (
         <a class="graphic graphic_picture graphicRef115902" href="/z/d/graphic/115902.html" rel="external">
          picture 2
         </a>
         ) and a bleeding diathesis. Pulmonary fibrosis similar to idiopathic pulmonary fibrosis occurs in patients with HPS types 1, 2, and 4. A granulomatous colitis resembling Crohn disease clinically and histologically occurs in patients with HPS types 1 and 4. Severe neutropenia and immunodeficiency have been reported in individuals with HPS types 2 and 10. Individuals with HPS also have an increased risk of skin cancer, in particular, squamous cell and basal cell carcinoma. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of HPS is suspected in a patient with skin and hair color lighter than that of other family members, early-onset nystagmus, and a history of easy bruising starting in infancy, epistaxis or gingival bleeding, or excessive bleeding after medical or surgical procedures. The demonstration of absent dense bodies on electron microscopy of platelets using the "whole mount" technique (available in specialized referral laboratories) establishes the diagnosis of HPS. Genetic testing, if available, can confirm the diagnosis and determine the HPS type. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – The management of patients with HPS involves lifelong sun protection measures and regular skin examination at 6- to 12-month intervals, starting in adolescence, for early detection and treatment of skin cancer. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Eye examinations should be performed frequently in the preschool years but can be reduced to yearly thereafter. Refractive errors are corrected with glasses or contact lenses. Extraocular muscle surgery may be needed to correct strabismus or nystagmus. Appropriate support in school is recommended.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Granulomatous colitis is treated with systemic corticosteroids and other anti-inflammatory agents used for the treatment of Crohn disease. (See
         <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">
          "Medical management of moderate to severe Crohn disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with HPS who develop pulmonary fibrosis may eventually require lung transplantation. (See
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1017112783">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges C Gail Summers, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Introne WJ, Huizing M, Malicdan MC, et al. Hermansky-Pudlak syndrome. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, Seattle, 1993.
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Chemaly S, Young LR. Hermansky-Pudlak Syndrome. Clin Chest Med 2016; 37:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merideth MA, Introne WJ, Wang JA, et al. Genetic variants associated with Hermansky-Pudlak syndrome. Platelets 2020; 31:544.
          </a>
         </li>
         <li class="breakAll">
          Orphanet rare diseases database entry on Hermansky-Pudlak syndrome. https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=79430 (Accessed on April 15, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witkop CJ, Nuñez Babcock M, Rao GH, et al. Albinism and Hermansky-Pudlak syndrome in Puerto Rico. Bol Asoc Med P R 1990; 82:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Velázquez-Díaz P, Nakajima E, Sorkhdini P, et al. Hermansky-Pudlak Syndrome and Lung Disease: Pathogenesis and Therapeutics. Front Pharmacol 2021; 12:644671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gahl WA, Brantly M, Kaiser-Kupfer MI, et al. Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak syndrome). N Engl J Med 1998; 338:1258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huizing M, Helip-Wooley A, Westbroek W, et al. Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics. Annu Rev Genomics Hum Genet 2008; 9:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li W, Hao CJ, Hao ZH, et al. New insights into the pathogenesis of Hermansky-Pudlak syndrome. Pigment Cell Melanoma Res 2022; 35:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loredana Asztalos M, Schafernak KT, Gray J, et al. Hermansky-Pudlak syndrome: Report of two patients with updated genetic classification and management recommendations. Pediatr Dermatol 2017; 34:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowman SL, Bi-Karchin J, Le L, Marks MS. The road to lysosome-related organelles: Insights from Hermansky-Pudlak syndrome and other rare diseases. Traffic 2019; 20:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White JG, Hess RA, Gahl WA, Introne W. Rapid ultrastructural detection of success or failure after bone marrow transplantation in the Chediak-Higashi syndrome. Platelets 2013; 24:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barak Y, Nir E. Chediak-Higashi syndrome. Am J Pediatr Hematol Oncol 1987; 9:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seward SL Jr, Gahl WA. Hermansky-Pudlak syndrome: health care throughout life. Pediatrics 2013; 132:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu T, Yuan Y, Bai D, et al. Genetic variants and mutational spectrum of Chinese Hermansky-Pudlak syndrome patients. Pigment Cell Melanoma Res 2021; 34:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu T, Yuan Y, Bai D, et al. The first Hermansky-Pudlak syndrome type 9 patient with two novel variants in Chinese population. J Dermatol 2021; 48:676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pennamen P, Le L, Tingaud-Sequeira A, et al. BLOC1S5 pathogenic variants cause a new type of Hermansky-Pudlak syndrome. Genet Med 2020; 22:1613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boeckelmann D, Wolter M, Käsmann-Kellner B, et al. A Novel Likely Pathogenic Variant in the BLOC1S5 Gene Associated with Hermansky-Pudlak Syndrome Type 11 and an Overview of Human BLOC-1 Deficiencies. Cells 2021; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pennamen P, Tingaud-Sequeira A, Michaud V, et al. Novel variants in the BLOC1S3 gene in patients presenting a mild form of Hermansky-Pudlak syndrome. Pigment Cell Melanoma Res 2021; 34:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toro J, Turner M, Gahl WA. Dermatologic manifestations of Hermansky-Pudlak syndrome in patients with and without a 16-base pair duplication in the HPS1 gene. Arch Dermatol 1999; 135:774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jardón J, Izquierdo NJ, Renta JY, et al. Ocular Findings in Patients with the Hermansky-Pudlak Syndrome (Types 1 and 3). Ophthalmic Genet 2016; 37:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simon JW, Adams RJ, Calhoun JH, et al. Ophthalmic manifestations of the Hermansky-Pudlak syndrome (oculocutaneous albinism and hemorrhagic diathesis). Am J Ophthalmol 1982; 93:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller MR, Rao S. Hermansky-Pudlak oculocutaneous albinism, clinical and genetic observations of six patients. Ophthalmic Paediatr Genet 1983; 3:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Summers CG, Knobloch WH, Witkop CJ Jr, King RA. Hermansky-Pudlak syndrome. Ophthalmic findings. Ophthalmology 1988; 95:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Izquierdo NJ, Townsend W, Hussels IE. Ocular findings in the Hermansky-Pudlak syndrome. Trans Am Ophthalmol Soc 1995; 93:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vicary GW, Vergne Y, Santiago-Cornier A, et al. Pulmonary Fibrosis in Hermansky-Pudlak Syndrome. Ann Am Thorac Soc 2016; 13:1839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Jesus Rojas W, Young LR. Hermansky-Pudlak Syndrome. Semin Respir Crit Care Med 2020; 41:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yokoyama T, Gochuico BR. Hermansky-Pudlak syndrome pulmonary fibrosis: a rare inherited interstitial lung disease. Eur Respir Rev 2021; 30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weitz N, Patel V, Tlougan B, et al. Metastatic cutaneous involvement of granulomatous colitis in Hermansky-Pudlak syndrome. Pediatr Dermatol 2013; 30:e278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvaggio HL, Graeber KE, Clarke LE, et al. Mucocutaneous granulomatous disease in a patient with Hermansky-Pudlak syndrome. JAMA Dermatol 2014; 150:1083.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Boer M, van Leeuwen K, Geissler J, et al. Hermansky-Pudlak syndrome type 2: Aberrant pre-mRNA splicing and mislocalization of granule proteins in neutrophils. Hum Mutat 2017; 38:1402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ammann S, Schulz A, Krägeloh-Mann I, et al. Mutations in AP3D1 associated with immunodeficiency and seizures define a new type of Hermansky-Pudlak syndrome. Blood 2016; 127:997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohammed M, Al-Hashmi N, Al-Rashdi S, et al. Biallelic mutations in AP3D1 cause Hermansky-Pudlak syndrome type 10 associated with immunodeficiency and seizure disorder. Eur J Med Genet 2019; 62:103583.
          </a>
         </li>
         <li class="breakAll">
          Witkop CJ, Quevedo WC, Fitzpatrick TB, King RA. Albinism. In: The Metabolic and Molecular Basis of Inherited Diseases, 6th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, 1989.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huizing M, Malicdan MCV, Wang JA, et al. Hermansky-Pudlak syndrome: Mutation update. Hum Mutat 2020; 41:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Botero JP, Chen D, Majerus JA, et al. Hermansky-Pudlak syndrome subtype 5 (HPS-5) novel mutation in a 65 year-old with oculocutaneous hypopigmentation and mild bleeding diathesis: The importance of recognizing a subtle phenotype. Platelets 2018; 29:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Power B, Ferreira CR, Chen D, et al. Hermansky-Pudlak syndrome and oculocutaneous albinism in Chinese children with pigmentation defects and easy bruising. Orphanet J Rare Dis 2019; 14:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Felipez LM, Gokhale R, Guandalini S. Hermansky-Pudlak syndrome: severe colitis and good response to infliximab. J Pediatr Gastroenterol Nutr 2010; 51:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshiyama S, Miki C, Araki T, et al. Complicated granulomatous colitis in a Japanese patient with Hermansky-Pudlak syndrome, successfully treated with infliximab. Clin J Gastroenterol 2009; 2:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erzin Y, Cosgun S, Dobrucali A, et al. Complicated granulomatous colitis in a patient with Hermansky-Pudlak syndrome, successfully treated with infliximab. Acta Gastroenterol Belg 2006; 69:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demirtas CO, Alahdab YO, Kani HT, et al. Treatment of Hermansky-Pudlak syndrome Associated granulomatous colitis with anti-TNF agents: case series and review of literature. Eur J Gastroenterol Hepatol 2019; 31:1597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lederer DJ, Kawut SM, Sonett JR, et al. Successful bilateral lung transplantation for pulmonary fibrosis associated with the Hermansky-Pudlak syndrome. J Heart Lung Transplant 2005; 24:1697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Chemaly S, O'Brien KJ, Nathan SD, et al. Clinical management and outcomes of patients with Hermansky-Pudlak syndrome pulmonary fibrosis evaluated for lung transplantation. PLoS One 2018; 13:e0194193.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 115158 Version 5.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Introne WJ, Huizing M, Malicdan MC, et al. Hermansky-Pudlak syndrome. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, Seattle, 1993.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27514596" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Hermansky-Pudlak Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32436471" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Genetic variants associated with Hermansky-Pudlak syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32436471" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Genetic variants associated with Hermansky-Pudlak syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2261023" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Albinism and Hermansky-Pudlak syndrome in Puerto Rico.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33841163" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Hermansky-Pudlak Syndrome and Lung Disease: Pathogenesis and Therapeutics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9562579" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18544035" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35129281" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : New insights into the pathogenesis of Hermansky-Pudlak syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29044644" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Hermansky-Pudlak syndrome: Report of two patients with updated genetic classification and management recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30945407" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The road to lysosome-related organelles: Insights from Hermansky-Pudlak syndrome and other rare diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22738378" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Rapid ultrastructural detection of success or failure after bone marrow transplantation in the Chediak-Higashi syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3296821" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Chediak-Higashi syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23753089" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hermansky-Pudlak syndrome: health care throughout life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32725903" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Genetic variants and mutational spectrum of Chinese Hermansky-Pudlak syndrome patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33543539" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The first Hermansky-Pudlak syndrome type 9 patient with two novel variants in Chinese population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32565547" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : BLOC1S5 pathogenic variants cause a new type of Hermansky-Pudlak syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34685610" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A Novel Likely Pathogenic Variant in the BLOC1S5 Gene Associated with Hermansky-Pudlak Syndrome Type 11 and an Overview of Human BLOC-1 Deficiencies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32687635" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Novel variants in the BLOC1S3 gene in patients presenting a mild form of Hermansky-Pudlak syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10411151" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Dermatologic manifestations of Hermansky-Pudlak syndrome in patients with and without a 16-base pair duplication in the HPS1 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24766090" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Ocular Findings in Patients with the Hermansky-Pudlak Syndrome (Types 1 and 3).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7065089" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Ophthalmic manifestations of the Hermansky-Pudlak syndrome (oculocutaneous albinism and hemorrhagic diathesis).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Hermansky-Pudlak oculocutaneous albinism, clinical and genetic observations of six patients
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3174014" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Hermansky-Pudlak syndrome. Ophthalmic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8719678" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Ocular findings in the Hermansky-Pudlak syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27529121" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Pulmonary Fibrosis in Hermansky-Pudlak Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32279294" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Hermansky-Pudlak Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33536261" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Hermansky-Pudlak syndrome pulmonary fibrosis: a rare inherited interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22471786" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Metastatic cutaneous involvement of granulomatous colitis in Hermansky-Pudlak syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24989352" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Mucocutaneous granulomatous disease in a patient with Hermansky-Pudlak syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28585318" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Hermansky-Pudlak syndrome type 2: Aberrant pre-mRNA splicing and mislocalization of granule proteins in neutrophils.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26744459" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Mutations in AP3D1 associated with immunodeficiency and seizures define a new type of Hermansky-Pudlak syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30472485" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Biallelic mutations in AP3D1 cause Hermansky-Pudlak syndrome type 10 associated with immunodeficiency and seizure disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30472485" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Biallelic mutations in AP3D1 cause Hermansky-Pudlak syndrome type 10 associated with immunodeficiency and seizure disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31898847" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Hermansky-Pudlak syndrome: Mutation update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29090612" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Hermansky-Pudlak syndrome subtype 5 (HPS-5) novel mutation in a 65 year-old with oculocutaneous hypopigmentation and mild bleeding diathesis: The importance of recognizing a subtle phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30791930" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Hermansky-Pudlak syndrome and oculocutaneous albinism in Chinese children with pigmentation defects and easy bruising.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20543722" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Hermansky-Pudlak syndrome: severe colitis and good response to infliximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26191810" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Complicated granulomatous colitis in a Japanese patient with Hermansky-Pudlak syndrome, successfully treated with infliximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16929618" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Complicated granulomatous colitis in a patient with Hermansky-Pudlak syndrome, successfully treated with infliximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31441797" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Treatment of Hermansky-Pudlak syndrome Associated granulomatous colitis with anti-TNF agents: case series and review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16210149" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Successful bilateral lung transplantation for pulmonary fibrosis associated with the Hermansky-Pudlak syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29547626" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Clinical management and outcomes of patients with Hermansky-Pudlak syndrome pulmonary fibrosis evaluated for lung transplantation.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
